← Back to list

The Differences Between Ultherapy and Ultherapy Prime

If You Had Ultherapy in the Past, What Has Changed in Ultherapy Prime?

Ultherapy Prime is the next-generation platform of Ultherapy launched in early 2025. While maintaining the identical mechanism of action (targeting the SMAS layer) and treatment depths as conventional Ultherapy, it has significantly enhanced treatment speed, imaging clarity, and procedural comfort. In essence, it can be understood as an upgrade where "the therapeutic backbone of efficacy remains intact, while the treatment experience has been refined."

This article compiles the questions most frequently searched by those who have previously undergone Ultherapy—including what has changed, why it targets the SMAS layer, pain levels, and optimal re-treatment intervals—all into a single comprehensive guide.

(The following content is intended solely for general medical informational purposes and does not guarantee specific therapeutic outcomes for any individual. Final decisions regarding whether and how to undergo treatment should always be made through an in-person consultation with a medical specialist.)


Ultherapy vs. Ultherapy Prime: What Exactly Has Changed?

The core biological principle remains identical; what has evolved is the 'treatment experience.' Because both devices deliver identical acoustic energy to depths of 1.5 mm, 3.0 mm, and 4.5 mm, the fundamental mechanism driving tissue lifting has not changed.

Three major enhancements are reported in Ultherapy Prime:
First, treatment speed is approximately 20% faster, allowing the same anatomical area to be treated in a shorter duration.
Second, the screen is approximately 35% larger with reduced imaging noise, enabling clinicians to visualize subcutaneous tissue structures with greater clarity. Furthermore, an avatar interface mirroring the patient's face allows for highly segmented, customized treatment planning.
Third, procedural comfort has improved with reported reductions in pain, post-treatment edema, and operational device noise.

In summary, Prime is a refined model engineered to deliver treatment 'faster, with sharper visualization, and in greater comfort,' while preserving the exact therapeutic principles that generate clinical results.

Does Ultherapy Prime Ultimately Target the SMAS Layer as Well?

Yes. Identical to legacy Ultherapy, Ultherapy Prime designates the SMAS (Superficial Musculo-Aponeurotic System) layer—located approximately 4.5 mm beneath the skin surface—as its primary therapeutic target.

SMAS stands for the 'Superficial Musculo-Aponeurotic System,' a continuous fibromuscular membrane that envelops the facial expression muscles. It lies significantly beneath the dermal layer, beneath the subcutaneous fat, and rests directly atop the facial muscles as a thin structural sheet.
During youth, this fascial layer firmly anchors and suspends facial structures. However, with aging, it becomes progressively lax due to gravity, chronic UV exposure, and repetitive mimetic muscle movements, causing the overlying cutaneous and adipose layers to drift downward together.
In surgical facial rhytidectomy (facelift), the exact anatomical layer that plastic surgeons dissect, lift, and suspend is this SMAS layer, which is universally recognized as the foundational anchor of facial lifting.

Why Did Previous Non-Ultherapy Liftings Feel Like They Regressed Quickly?

Because contracting surface-layer collagen alone cannot effectively suspend an already lax and descended SMAS layer. Thermal energy simply failed to reach the deeper anatomical scaffolding that serves as the root cause of tissue sagging.

Many generic lifting devices concentrate energy solely within shallow depths, such as the dermis and superficial subcutaneous fat. While patients may perceive an immediate tightening sensation following treatment, therapeutic longevity remains fundamentally limited unless the SMAS layer—the true origin of sagging—is directly addressed. To use an architectural analogy, it is akin to applying new wallpaper over a structure whose load-bearing framework is tilting.
Ultherapy Prime adopts a fundamentally distinct paradigm by delivering acoustic energy beyond superficial layers directly into the SMAS, contracting and regenerating the fascial sheet itself.

How Does Ultherapy Prime's Ultrasound Reach a Depth of 4.5 mm?

It utilizes High-Intensity Focused Ultrasound (HIFU) technology to converge broadly propagating acoustic waves into a singular focal point, traversing intervening superficial tissues harmlessly and releasing thermal energy exclusively at calibrated depths. This principle mirrors using a magnifying glass to converge sunlight onto a single focal point.

These ultrasound waves pass through the epidermis and dermis with minimal thermal deposition until reaching target focal depths (typically 1.5 mm, 3.0 mm, and 4.5 mm), where energy intensely concentrates. Clinical literature reports that temperatures reach approximately 60°C to 70°C at each focal coagulation zone—the optimal thermal window for denaturing compromised collagen and stimulating robust neocollagenesis. Histologically, sharply demarcated Thermal Coagulation Points (TCPs) are generated at the target site.
Unlike lasers or radiofrequency, ultrasound can be converged to precise depths dictated by acoustic tissue density differentials, making it possible to spare the cutaneous surface entirely while generating therapeutic heat strictly at target depths.

Ultherapy Was Painful in the Past—Is Prime Less Painful?

Published technical data describe Prime as featuring reduced intra-procedural pain, decreased post-treatment edema, and lowered operating acoustic noise. However, because pain perception is highly subjective and varies according to anatomical region and energetic parameters, specific individual discomfort should be evaluated during pre-treatment consultation.

In terms of procedure velocity, Prime delivers thermal coagulation points and energy pulses more rapidly, achieving an approximate 20% reduction in total procedure time. A shorter treatment duration naturally reduces the cumulative physical and psychological burden experienced during treatment of the same area. Furthermore, Prime is noted for enabling more precise micro-adjustments in delicate, intricate zones such as the periorbital/infraorbital area and mandibular contour.


What Improvements Have Been Made to DeepSEE™ Imaging in Prime?

Prime features an approximately 35% larger display coupled with substantially reduced image noise, allowing operators to irradiate energy while visualizing subcutaneous tissue architecture with heightened clarity.

The real-time ultrasound visualization (DeepSEE™) native to the Ultherapy platform allows clinicians to visually confirm the exact depth and location of the SMAS layer throughout treatment—often likened to 'driving with high-definition GPS navigation.' In Prime, a patient-specific avatar-based interface has been integrated to allow clinicians to formulate and execute granular, customized shot distribution algorithms. Nonetheless, visualization technology itself does not inherently guarantee clinical outcomes; operator diagnostic expertise and tailored depth/energy parameters remain paramount.

When Do Clinical Results Begin to Appear? (Is the Timeline Identical to Past Experiences?)

Because the biological mechanism of action is identical, the clinical timeline follows a trajectory very similar to legacy Ultherapy. As focused energy reaches the SMAS, micro-thermal stimulation (TCPs) is established, and the body's natural wound-healing cascade gradually synthesizes new collagen and elastin over several weeks to months.

A histological study documented that by post-treatment day 90, active fibroblasts and mature collagen fibrils significantly increased around thermal coagulation points, with dense recruitment of HSP47-positive fibroblasts and higher neo-elastin synthesis compared to day 14. In addition, manufacturer-cited scientific data indicate that the rate of collagen synthesis in treated tissue increased by an average of approximately 1.4-fold compared to untreated controls. This biological timeline explains why visible lifting becomes substantially more noticeable 1 to 2 months post-procedure, yielding remodeled collagen characterized by a remarkably dense, organized structural matrix.

Is Ultherapy Prime Also an FDA-Cleared Device?

The Ultherapy (Ulthera) platform represents a medical device family with established U.S. FDA clearances. The inaugural system received initial FDA clearance via the De Novo pathway in 2009 for non-invasive eyebrow lifting.

Subsequent clinical indications expanded to include neck and submental tissue lifting in 2012, real-time ultrasound visualization in 2013, and décolletage rhytid improvement in 2014. The platform is classified under the focused ultrasound category (Product Code OHV, 21 CFR 878.4590). Prime represents the newest platform from the manufacturer (Merz Aesthetics). When utilized domestically, please refer to corresponding regional regulatory approvals (such as Korea MFDS) and medical advertisement standards.

Legacy Ultherapy vs. Ultherapy Prime: Comprehensive Comparison

Category

Conventional Ultherapy

Ultherapy Prime

Mechanism of Action

HIFU targeting SMAS layer

Identical

Treatment Depths

1.5 mm · 3.0 mm · 4.5 mm

Identical

Focal Temperature (Literature)

Approximately 60°C ~ 70°C

Identical

Treatment Speed

Baseline reference

Approximately 20% faster

Imaging & Display

Conventional display

35% larger screen, reduced noise, avatar interface

Procedural Comfort

Baseline reference

Reported reductions in pain, swelling, and noise

Delicate Zone Control

Available

Enhanced fine micro-adjustments (infraorbital, jawline)

Launch Timeline

Previous generation

Late 2024 / Early 2025

(The above table provides a standardized comparison; actual clinical outcomes and sensory experiences will vary depending on individual patient skin physiology, device parameters, and clinical conditions.)

How Long Do Results Last? When Should Re-Treatment Be Considered?

According to published clinical reviews, therapeutic results endure for an average of approximately 2 years, though individual variance is substantial (younger cohorts typically range between 18–24 months, whereas older cohorts range between 12–15 months). Optimal re-treatment timing should integrate this longevity timeline with ongoing individual skin changes and physician consultations.

Furthermore, Ultherapy Prime does not resolve every category of tissue laxity. Severely redundant, ptotic skin or excessive deep adiposity may not achieve sufficient correction through energy devices alone, in which case surgical rhytidectomy or alternative modalities may be more clinically indicated. In our clinical practice, we first evaluate the patient's anatomical presentation to determine whether Prime is suitable as monotherapy or if a multi-modal combination is warranted. Even with the same device, clinical outcomes vary dramatically based on depth selection, energy density, and vector shot spacing; therefore, understanding anatomical principles and therapeutic timing takes precedence over device branding.

Frequently Asked Questions (FAQ)

Q. If I previously received Ultherapy, what changes when treated with Prime?

A. The therapeutic mechanism and treatment depths remain identical. The key differences lie in approximately 20% faster treatment speed, a 35% larger display with superior image clarity, and noticeably enhanced procedural comfort.

Q. To which anatomical depths does Ultherapy Prime deliver energy?

A. Identical to legacy Ultherapy, it targets 1.5 mm, 3.0 mm, and 4.5 mm depths, with 4.5 mm corresponding directly to the SMAS layer—the anatomical cornerstone of lifting.

Q. Is Prime genuinely less painful?

A. Published data indicate reductions in procedural pain, post-treatment edema, and operational noise. However, individual pain thresholds vary widely across anatomical sites and parameter settings, making personalized pre-treatment consultation essential.

Q. When do results manifest, and how long do they last?

A. Rather than immediately post-treatment, visible lifting develops progressively over 2 to 3 months, continuing through 6 months. Average therapeutic longevity is reported at approximately 2 years in clinical literature, subject to individual variation.

The true therapeutic core of Ultherapy Prime remains unequivocally the SMAS layer. It should be understood as an evolved platform that preserves the foundational principle of treating deep structural anatomy rather than superficial skin, while substantially upgrading procedural speed, visualization precision, and patient comfort. However, because clinical outcomes depend heavily on customized energy configurations, shot spacing, and individual patient physiology, an accurate pre-treatment diagnostic evaluation is essential. If you are contemplating re-treatment while reflecting on past Ultherapy experiences, we advise focusing on fundamental anatomical principles rather than device nomenclature alone, selecting the optimal modality tailored to your unique skin profile through an in-depth physician consultation. For inquiries, please contact Lieul Clinic.

References & Sources

• Fabi SG, et al. Customized Treatment Using Microfocused Ultrasound with Visualization... Pan-Asian Adaptation of the Expert Panel's Gold Standard Consensus. PMC8211327. https://pmc.ncbi.nlm.nih.gov/articles/PMC8211327/

• Marquardt K, et al. Microfocused Ultrasound With Visualization Induces Remodeling of Collagen and Elastin Within the Skin. Journal of Cosmetic Dermatology, 2025. PMC11743342. https://pmc.ncbi.nlm.nih.gov/articles/PMC11743342/

• Skin physiology and safety of microfocused ultrasound with visualization for improving skin laxity. PMC6336023. https://pmc.ncbi.nlm.nih.gov/articles/PMC6336023/

• Ultherapy. Mechanism of Action – Optimized Neocollagenesis. https://ultherapy.com/physicians/optimized-neocollagenesis

• Ulthera / BioSpace. Ulthera Receives First-Ever FDA Clearance to Market Ultrasound Technology for Facial Aesthetic Improvement (2009). https://www.biospace.com/ulthera-receives-first-ever-fda-clearance-to-market-ultrasound-technology-for-facial-aesthetic-improvement

• Healio Dermatology. FDA approves Ulthera System for noninvasive treatment of neck, submental tissue (2012). https://www.healio.com/news/dermatology/20121012/asdsfda1_10_3928_1081_597x_20121001_12

• MINE Clinic. Ultherapy Results: Does It Really Work? (2026 Evidence). https://mineclinic.com/blog/skin/ultherapy/scientific-evidence-of-ultherapy-results-complete-clinical-guide/

• Wave Plastic Surgery. Ultherapy Prime vs. Ultherapy — 2025 Technology Comparison. https://waveplasticsurgery.com/ultherapy-prime-vs-ultherapy/

Author Profile & Medical Institution

Author: In-Yong Kim, M.D.
Specialty: Board-Certified Dermatologist
Medical Institution: Lieul Clinic (
리을피부과의원)

Author Profile & Credentials:
• Board-Certified Dermatologist
• Official Clinical Advisory Board Member (ABM) for Ultherapy Prime
• Official Clinical Advisory Board Member (MTL) for Thermage FLX
• Official Clinical Advisory Board Member for Radiesse
• Official Clinical Advisory Board Member for HILOWAVE
• Official Clinical Advisory Board Member for Sculptra
• Official Clinical Advisory Board Member for Restylane

Click here for a quick consultation